Characterization of phorbol esters activity on individual mammalian protein kinase C isoforms, using the yeast phenotypic assay.

[1]  J. Sullivan,et al.  2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexanamide (NPC 15437): A selective inhibitor of protein kinase C , 1991, Agents and Actions.

[2]  L. Saraíva,et al.  Isoform-selectivity of PKC Inhibitors Acting at the Regulatory and Catalytic Domain of Mammalian PKC-α, -βI, -δ, -η and -ζ , 2003 .

[3]  M. Kazanietz,et al.  Divergence and complexities in DAG signaling: looking beyond PKC. , 2003, Trends in pharmacological sciences.

[4]  E. Sousa,et al.  Inhibition of α, βI, δ, η and ζ Protein Kinase C Isoforms by Xanthonolignoids , 2003, Journal of enzyme inhibition and medicinal chemistry.

[5]  Y. Nishizuka,et al.  Protein kinase C isotypes and their specific functions: prologue. , 2002, Journal of biochemistry.

[6]  M. Kazanietz,et al.  Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy. , 2001, Current pharmaceutical design.

[7]  M. Reilly,et al.  Pharmacology of the receptors for the phorbol ester tumor promoters: multiple receptors with different biochemical properties. , 2000, Biochemical pharmacology.

[8]  B. Webb,et al.  Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis , 2000, British journal of pharmacology.

[9]  M. Musashi,et al.  The role of protein kinase C isoforms in cell proliferation and apoptosis. , 2000, International journal of hematology.

[10]  G. King,et al.  Identification of PKC-isoform-specific biological actions using pharmacological approaches. , 2000, Trends in pharmacological sciences.

[11]  H. Majewski,et al.  The structural requirements for phorbol esters to enhance serotonin and acetylcholine release from rat brain cortex , 1999, British Journal of Pharmacology.

[12]  Xiao-ling Guo,et al.  Protein Kinase Cδ-dependent Induction of Manganese Superoxide Dismutase Gene Expression by Microtubule-active Anticancer Drugs* , 1998, The Journal of Biological Chemistry.

[13]  C. Pears,et al.  Isoform specificity of activators and inhibitors of protein kinase C γ and δ , 1997 .

[14]  Johann Hofmann,et al.  The potential for isoenzyme‐selective modulation of protein kinase C , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  D. Fabbro,et al.  Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumor-promoting and nontumor-promoting agents. , 1997, Biochemical pharmacology.

[16]  H. Riedel,et al.  Activation of conventional mammalian protein kinase C isoforms expressed in budding yeast modulates the cell doubling time--a potential in vivo screen for protein kinase C activators. , 1996, Cancer Detection and Prevention.

[17]  P. Parker,et al.  Characterization of phorbol ester binding to protein kinase C isotypes. , 1995, Molecular pharmacology.

[18]  H. Riedel,et al.  Differential protein kinase C ligand regulation detected in vivo by a phenotypic yeast assay , 1995, Molecular carcinogenesis.

[19]  D. Fabbro,et al.  Comparison of different tumour promoters and bryostatin 1 on protein kinase C activation and down-regulation in rat renal mesangial cells. , 1994, Biochemical pharmacology.

[20]  P. Parker,et al.  Expression of mammalian protein kinase C in Schizosaccharomyces pombe: isotype-specific induction of growth arrest, vesicle formation, and endocytosis. , 1994, Molecular biology of the cell.

[21]  A. Parissenti,et al.  Phorbol ester activation of functional rat protein kinase C β‐1 causes phenotype in yeast , 1993, Journal of cellular biochemistry.

[22]  A. Parissenti,et al.  Stimulation of calcium uptake in Saccharomyces cerevisiae by bovine protein kinase C alpha. , 1993, The Journal of biological chemistry.

[23]  J. Exton,et al.  Purification and characterization of the zeta isoform of protein kinase C from bovine kidney. , 1992, The Journal of biological chemistry.

[24]  U. Kikkawa,et al.  Catalytic properties of yeast protein kinase C: difference between the yeast and mammalian enzymes. , 1992, Journal of Biochemistry (Tokyo).

[25]  P. Parker,et al.  Effect of phorbol esters on protein kinase C-zeta. , 1992, The Journal of biological chemistry.

[26]  J. Sullivan,et al.  2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl] methyl)hexanamide (NPC 15437): a novel inhibitor of protein kinase C interacting at the regulatory domain. , 1992, Molecular pharmacology.

[27]  D. Burns,et al.  Protein kinase C contains two phorbol ester binding domains. , 1991, The Journal of biological chemistry.

[28]  R. Patch,et al.  Substituted 2-(aminomethyl)piperidines: a novel class of selective protein kinase C inhibitors. , 1991, Journal of Medicinal Chemistry.

[29]  P. Parker,et al.  Activation of the PKC‐isotypes α, β1, γ, δ, and ε by phorbol esters of different biological activities , 1991 .

[30]  P. Parker,et al.  Phorbol ester activation of the isotypes of protein kinase C from bovine and rat brain. , 1991, Biochemical Society Transactions.

[31]  J. Herbert,et al.  Chelerythrine is a potent and specific inhibitor of protein kinase C. , 1990, Biochemical and biophysical research communications.

[32]  Y. Nishizuka,et al.  Protein kinase C in Saccharomyces cerevisiae: comparison with the mammalian enzyme. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Koehler,et al.  Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Terrence P. Kenakin,et al.  A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .

[35]  J. Darbon,et al.  Phorbol esters inhibit the proliferation of MCF-7 cells. Possible implication of protein kinase C. , 1986, Biochemical pharmacology.

[36]  R. Liskamp,et al.  Computer-assisted molecular modeling of tumor promoters: rationale for the activity of phorbol esters, teleocidin B, and aplysiatoxin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Murata,et al.  Transformation of intact yeast cells treated with alkali cations , 1983 .

[38]  J. Niedel,et al.  Phorbol diester receptor copurifies with protein kinase C. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. Marks,et al.  Effects of the phorbol ester 4-O-methyl-12-O-tetradecanoylphorbol-13-acetate on mouse skin in vivo: evidence for its uselessness as a negative control compound in studies on the biological effects of phorbol ester tumor promoters. , 1982, Cancer research.

[40]  G. Todaro,et al.  Specific high affinity cell membrane receptors for biologically active phorbol and ingenol esters , 1980, Nature.

[41]  P. Blumberg,et al.  Characterization of specific binding of [3H]phorbol 12,13-dibutyrate and [3H]phorbol 12-myristate 13-acetate to mouse brain. , 1980, Cancer research.

[42]  T. Slaga,et al.  Studies on the mechanism of skin tumor promotion: evidence for several stages in promotion. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[43]  P. Blumberg,et al.  Specific binding of phorbol ester tumor promoters to mouse skin , 1980, Cell.